-
2 weeks ago | 
idse.net | Marie Rosenthal
By Marie Rosenthal, MSHHS Secretary Robert F. Kennedy Jr. “retired” 17 people from the Advisory Committee on Immunization Practices (ACIP) on June 9, and appointed eight people several days later without going through the usual vetting process, which can take months. The secretary of the Department of Health and Human Services said he disbanded the ACIP to restore the public’s trust in governmental advisory bodies and agencies.
-
3 weeks ago | 
idse.net | Meaghan Lee Callaghan |Marie Rosenthal
By Meaghan Lee Callaghan and Marie Rosenthal, MSInstead of removing the COVID-19 vaccine from the childhood immunization schedule, the CDC said parents and clinicians should use shared clinical decision-making to determine whether their healthy children should receive the primary vaccine.
-
1 month ago | 
idse.net | Marie Rosenthal
By Marie Rosenthal, MSIn a unanimous decision, the FDA’s Vaccines and Related Biological Products Advisory Committee recommended the JN.1 and/or a specific JN.1-lineage strain should be used in the 2025-2026 formula for updated COVID-19 vaccines. As SARS-CoV-2 , it has been mutating with one strain after another becoming dominant. The delta strain became dominant in India in 2020, but by around May 2021, it was the dominant strain around the world.
-
1 month ago | 
pharmacypracticenews.com | Marie Rosenthal
Originally published by our sister publication Infectious Disease Special EditionBy Marie Rosenthal, MSThe CDC accepted the advice of the Advisory Committee on Immunization Practices (ACIP), which made new and updated recommendations about the use of vaccines against respiratory syncytial virus (RSV), meningococcal disease and chikungunya.
-
1 month ago | 
pharmacypracticenews.com | Marie Rosenthal
Originally published by our sister publication Infectious Disease Special EditionBy Marie Rosenthal, MSWe got it wrong. The acceptance was only for CHKV. We apologize for the error. The CDC accepted the recommendation of the Advisory Committee on Immunization Practices (ACIP) for the chikungunya vaccine. It has yet to make a decision on the vaccines for respiratory syncycial virus and meningococcal diseases.
-
1 month ago | 
idse.net | Marie Rosenthal
By Marie Rosenthal, MSThe CDC accepted the advice of the Advisory Committee on Immunization Practices (ACIP), which made new and updated recommendations about the use of vaccines against respiratory syncytial virus (RSV), meningococcal disease and chikungunya. The CDC did not announce that the recommendations were accepted, but just added a two-line notice on the ACIP’s webpage, under the heading Recent Meeting Recommendations.
-
1 month ago | 
idse.net | Marie Rosenthal
By Marie Rosenthal, MSThe total number of measles cases as of May is more than three times higher than previously reported all of last year. As of May 1, 2025, a total of 935 cases of measles have been confirmed by 30 jurisdictions in the United States; by Dec. 31, 2024, a total of 285 measles cases were reported by 33 jurisdictions.
-
2 months ago | 
painmedicinenews.com | Marie Rosenthal
Originally published by our sister publication Infectious Disease Special EditionMore data from the STOMP (Study of Tecovirimat for Mpox) trial presented at CROI 2025, in San Francisco, confirmed that tecovirimat does not reduce the time to clinical resolution of clade II mpox lesions or improve pain among adults, according to Timothy Wilkin, MD, MPH, a professor of medicine and the chief of the Division of Infectious Diseases and Global Public Health at the University of
-
2 months ago | 
pharmacypracticenews.com | Marie Rosenthal
Originally published by our sister publication Infectious Disease Special EditionBy Marie Rosenthal, MSThe CDC’s Advisory Committee on Immunization Practices voted to recommend the virus-like particle-based chikungunya vaccine, recombinant (CHIK-VLP; Vimkunya, Bavarian Nordic) for certain populations. However, the CDC has not acted yet on this or other recommendations the ACIP made April 16.
-
2 months ago | 
pharmacypracticenews.com | Marie Rosenthal
Ensitrelvir, an antiviral being developed to prevent COVID-19, reduced the risk of developing the infection by 67% in uninfected people after exposure to SARS-CoV-2 compared with placebo at day 10, according to results presented at CROI 2025, held in San Francisco (abstract 200). The 67% reduction is “super exciting,” said Diane Havlir, MD, the CROI chair, and the chief of the HIV, Infectious Diseases and Global Medicine Division at Zuckerberg San Francisco General Hospital and Trauma Center.
